• Clarivate completed the sale of its Life Sciences & Healthcare segment to Altaris for $600 million, previously announced July 6, 2026.
• Divestiture leaves Clarivate focused on its Academia & Government segment and Intellectual Property segment.
• Proceeds earmarked for debt reduction, strengthening the balance sheet, and improving financial flexibility.
• Full-year 2026 guidance will be updated to reflect the divestiture when third-quarter results are released Nov. 3, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clarivate plc published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610061615PR_NEWS_USPR_____NY64200) on October 06, 2026, and is solely responsible for the information contained therein.